Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -6.61 percent to $26.01 Friday on volume of 3.37million shares. The intra-day range of the stock was $25.60 to $28.25. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has a market capitalization of $2.54billion.

Shares of Clovis Oncology Inc (NASDAQ:CLVS) have been given a consensus rating of “Buy” by the seven analysts that are covering the company, Analyst Ratings.Net reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $90.40. Clovis Oncology Inc (NASDAQ:CLVS)’s stock on Mar 21, 2014 reported a decrease of -6.86% to the closing price of $79.91. Its fifty two weeks range is $27.17 -$93.33. The total market capitalization recorded $2.71billion. The overall volume in the last trading session was 773.5K shares. In its share capital, CLVS has 31.85million outstanding shares.

Shares of InterMune Inc (NASDAQ: ITMN) , a biopharmaceutical company focused on developing therapies to treat orphan fibrotic diseases, jumped as much as 17% after privately held rival Boehringer Ingelheim unveiled results from its two late-stage studies involving nintedanib as a treatment for idiopathic pulmonary fibrosis, or IPF. InterMune Inc (NASDAQ:ITMN) stock performance was 5.33% in last session and finished the day at $34.60. Traded volume was 7.86million shares in the last session and the average volume of the stock remained 3.08million shares. The beta of the stock remained 4.08. InterMune Inc (NASDAQ:ITMN) insider ownership is 0.20%.

Shares of Synageva BioPharma Corp (NASDAQ:GEVA) have received an average rating of “Hold” from the nine brokerages that are covering the stock, Analyst Ratings.Net reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. On Friday, shares of Synageva BioPharma Corp (NASDAQ:GEVA) dropped -9.48% to close the day at $90.67. Company return on investment (ROI) is -22.30% and its monthly performance is recorded as -16.71%. Synageva BioPharma Corp (NASDAQ:GEVA) quarterly revenue growth is 37.75%.